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Extracellular-released vesicles (EVs), such as microvesicles (MV) and exosomes (Exo)
provide a new type of inter-cellular communication, directly transferring a ready to use
box of information, consisting of proteins, lipids and nucleic acids. In the nervous
system, EVs participate to neuron-glial cross-talk, a bidirectional communication
important to preserve brain homeostasis and, when dysfunctional, involved in several
CNS diseases. We investigated whether microglia-derived EVs could be used to transfer
a protective phenotype to dysfunctional microglia in the context of a brain tumor.
When MV, isolated from microglia stimulated with LPS/IFNγ were brain injected in
glioma-bearing mice, we observed a phenotype switch of tumor associated myeloid
cells (TAMs) and a reduction of tumor size. Our findings indicate that the MV cargo,
which contains upregulated transcripts for several inflammation-related genes, can
transfer information in the brain of glioma bearing mice modifying microglial gene
expression, reducing neuronal death and glioma invasion, thus promoting the recovery
of brain homeostasis.
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INTRODUCTION
Cellular communication has been recently enriched by a new mechanism, that use the cargo
transported by extracellular membrane vesicles (EVs). EVs include exosomes (Exo, 10–100 nm
diameter), microvesicles (MV, 100–1000 nm) and apoptotic “blebs” (1–2 mm). EVs are produced
by all cell types and their production dynamically changes in number and content in response to
specific environmental signals. The content of EVs, considered true metabolic units, is released into
the cytoplasm of receiving cells, where they mediate several functional effects (Iraci et al., 2017).
In the brain, EVs modulate synaptic activity and neuronal communication (Korkut et al., 2013;
Chivet et al., 2014), and also contribute to spreading disease in several CNS pathologies, such
as multiple sclerosis (Carandini et al., 2015), Alzheimer’s disease (Aguzzi and Rajendran, 2009;
Gouwens et al., 2018), prion disease (Fevrier et al., 2004), and Huntington’s disease (Zhang et al.,
2016). Neurocentric vision in acute and chronic diseases of the CNS turned out to be insufficient to
explain the mechanisms responsible for several disease onset and progression. The role played by
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non-neuronal cells, such as astrocytes and microglia, which
are in constant communication with neurons to monitor brain
parenchyma through their processes, actively contribute to
maintain cerebral homeostasis.
EVs released by microglia, similarly to EVs released by
macrophages, recapitulate, in their cargo, the inflammatory
information of the donor cell (Garzetti et al., 2014;
Cunha et al., 2016).
Microglial cells acquire a dysfunctional phenotype in many
CNS pathologies, losing their ability to monitor and preserve
brain homeostasis. In the context of glioma, tumor associated
myeloid cells (TAMs) modify their phenotype and local
microenvironment toward a pro-tumor, anti-inflammatory state
supporting tumor cell proliferation, survival, and invasion (da
Fonseca and Badie, 2013).
In this work, we investigated the role of MV released by
polarized microglia on the modulation of microglia state in vivo,
to verify the hypothesis to use MV to help host microglia to
reacquire a homeostatic state in the context of glioma. At this aim
EVs, and in particular microvesicles (MV) and exosomes (Exo)
released by microglia in inflammatory conditions were isolated
and analyzed for their in vitro and in vivo effects in glioma
bearing mice. We demonstrated that in vitro, microglia derived
LPS/IFNγ-MVs reduced the expression of anti-inflammatory
genes in IL4-treated microglia. In vivo, LPS/IFNγ-MVs injected
in the brain of mice with glioma reduced the anti-inflammatory
phenotype of TAMs and significantly reduced tumor size and
tumor induced neurotoxicity. We suggest that the cargo of
LPS/IFNγ-MV, which contains specific mRNA for inflammatory
genes, transfer this information to recipient cells modifying their
gene expression profile toward a protective one. Altogether, these
findings demonstrate that the administration of exogenous EVs
could be a valuable approach to transfer protective signals to
TAMs, restoring the homeostatic microglia phenotype.
RESULTS
Dimensional and Morphological
Analyses of EVs Derived From Microglia
EVs, in particular microvesicles (MV) and exosomes (Exo), were
obtained from BV2 cell line and primary mouse microglia.
EV sizes were measured by Dynamic Light Scattering (DLS)
performed at a constant temperature of 15◦C. The CONTIN
distribution demonstrated that BV2-derived MV (Figure 1A) had
a polydispersity of 20%. The intensity-weighted distribution of
hydrodynamic diameter shows that the main population peaked
around 300 nm, providing 90% of the total scattered intensity, as
evidenced by the integral of the distribution reported in the inset
of Figure 1A. In MV released by primary microglia (Figure 1B) a
polydispersity of 30–40% was obtained and two main populations
were identified: the first peaked at 250 nm and the second at
880 nm. The distribution integral (inset of Figure 1B) highlights
that 20% of the total scattered intensity is due to the smallest
population, while 50% is due to the largest one. Exo had a
polydispersity around 30–40%. Due to their size, the volume-
weighted is the most accurate distribution to obtain qualitative
information on sample composition. Seventy percent of Exo has
a mean size of 34± 4 nm (derived from BV2 cells, Figure 1C) and
of 39± 4 nm (derived from primary microglial cells, Figure 1D),
while larger aggregates provide little contribution to the volume-
weighted distribution, as evidenced in the insets of Figures 1C,D.
For both populations there is a 30% of contribution to the overall
scattered intensity due to larger aggregates.
EVs derived from BV2 cells were analyzed at the transmission
electron microscopy: data shown in Figure 1E identify the
typical round vesicle morphology and underlined a scattered
composition in size, with the presence of aggregates (Figure 1E),
that confirmed DLS data above reported.
MV Derived From Microglia Treated With
LPS/IFNγ Reduce Migration and Invasion
of GL261 Glioma Cells and Are
Neuroprotective Against Glioma
Excitotoxicity in vitro
Cultured primary microglia and BV2 cells were treated with
LPS/IFNγ or IL 4. We previously verified microglia polarization
by mRNA analysis (Grimaldi et al., 2016); we confirmed these
data showing that LPS/IFNγ-treated cells increased NO release
and that IL-4-treated cells increased Arg1 expression and
activity (Supplementary Figure S1 and related Supplementary
Methods). Quantification of MV released by control (C-MV),
LPS/IFNγ-treated (LPS/IFNγ-MV), and IL4-treated BV2 cells
(IL4-MV) was measured by Laser Transmission Spectroscopy
(LTS) (Li et al., 2010). LTS measurements showed that the
number (N) of MV/cell in these three conditions was not
significantly different (Figure 2A). MV were then tested to
verify their ability to interfere with glioma cell migration
and proliferation. Data shown in Figure 2B illustrate that
GL261 migration was impaired by LPS/IFNγ-MV, while GL261
migration increased upon IL 4-MV treatment, at 24 and 48 h.
In contrast, neither LPS/IFNγ-Exo nor IL 4-Exo (released by
primary microglia) affected GL261 migration (Supplementary
Figure S2). Based on these results, for successive experiments we
decided to focus our interest only on the effect of MV. Similarly to
migration, results obtained on CXCL12-induced GL261 invasion,
demonstrated inhibitory effects of LPS/IFNγ-MV and no effects
of IL 4-MV (Figure 2C). Note that basal GL261 invasion
was significant reduced in the presence of LPS/IFNγ-MV and
was significant enhanced in the presence of IL 4-MV. These
data indicate that microglia-derived MVs modulate glioma cell
movement and invasion.
To investigate the effect of MV on glioma cell viability and
proliferation, MTT assay and BrdU staining were performed.
Results reported in Figure 2D show that neither LPS/IFNγ-MV
nor IL 4-MV directly modulate GL261 viability, at 24, 48, 72, or
96 h. Similarly, no changes in proliferation rate were induced by
LPS/IFNγ-MV or by IL 4-MV, measured by bromodeoxyuridine
(BrdU) staining after 24 h (Figure 2E) and 48 h (data not
shown). To investigate whether microglia-derived MV could
exert indirect effects on glioma, cells were co-cultured with a
mixed neuroglia culture in the presence of LPS/IFNγ-MV, for
18 h: in these conditions a reduction of GL261 viability was
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FIGURE 1 | Hydrodynamic diameter distribution (d) as obtained from CONTIN analysis of the intensity autocorrelation curves, for microvesicles obtained from BV2
microglia cell line (A) and from primary murine microglia (B), for exosomes from BV2 (C) and primary microglia (D), reported as intensity-weighted distribution. The
overall normalized integral of the distribution is also reported in the inset of the relative panels (SID, scattering intensity distribution; SII, scattering intensity integral).
Gray lines are fits through Log-normal distribution. (E) Transmission electron microscopy of EVs derived from BV2 cells. Bar = 100 nm, direct magnification 40000×,
print magnification 213000×.
observed (Figure 2F), indicating an indirect effect of MV on
glioma cell viability. In these same co-culture experiments, we
also analyzed the effect of MV on neuron survival and observed
(Figure 2G) that LPS/IFNγ-MV counteracted GL261-induced
neurotoxicity, while IL 4-MV were ineffective.
Microglia-Derived LPS/IFNγ-MV Reduce
Tumor Size in Mice
The above reported data prompted us to investigate the
effect of LPS/IFNγ-MV in a mouse model of glioma. At
this aim, GL261 cells were brain injected in the striatal
region of the right hemisphere and, after 7 and 14 days,
primary microglia-derived MV were infused in the tumor
region via an implanted cannula. Fifteen days after tumor
injection (Figure 3) LPS/IFNγ-MV treated mice had a
significant reduction of tumor size while mice treated
with IL 4-MV significantly increased the size of their brain
tumors. Similar results were obtained with BV2-derived MV
(Supplementary Figure S3). To investigate whether these
effects on tumor size were mediated by alterations of GL261
cell proliferation, mice treated as in Figure 3 were given BrdU
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FIGURE 2 | (A) Density distribution of BV2-derived MVs, together with the transmission coefficient as a function of the wavelength (inset). The integral of the density
distribution showed the number of MV per ml. Normalizing, the number of vesicles produced by each cell in control condition is N = 1.5 × 104 (C-MV), with LPS/IFNγ
is N = 1.4 × 104 (LPS/IFNγ-MV), with IL4 is N = 1.2 × 104 (IL4-MV). (B) GL261 glioma cells were treated with MV obtained from untreated microglia (C-MV),
microglia treated with LPS/IFNγ (LPS/IFNγ-MV) and IL 4 (IL 4-MV) and a wound healing assay was performed. GL261 migration was measured 24 and 48 h after
treatment, data are expressed as mean percentage of wound healing area ± SE, N = 4, ∗P < 0.001 vs. C-MV (one way analysis of variance, Holm-Sidak method).
On the right, representative wound healing assay on GL261 cells at 0 h and after 24 and 48 h of C-MV, LPS/IFNγ-MV and IL 4-MV treatment. (C) GL261 cells were
assayed for basal invasion (C) and CXCL12-induced invasion in presence of MV obtained from untreated microglia (C-MV), microglia treated with LPS/IFNγ
(Continued)
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FIGURE 2 | Continued
(LPS/IFNγ-MV) and IL 4 (IL 4-MV) in a Boyden chamber system. GL261 invasion was measured as mean percentage ± SE, N = 4; ∗P < 0.05 and ∗∗P < 0.001 (one
way analysis of variance, Holm-Sidak method). (D) GL261 cells were assayed for cell viability without MV (no-MV), in presence of MV obtained from untreated
microglia (C-MV), microglia treated with LPS/IFNγ (LPS/IFNγ-MV) and IL 4 (IL 4-MV) by MTT analysis. Cells were analyzed 0, 24, 48, 72, and 96 h after plating.
Viability was reported in optical density (OD) mean ± SE, N = 4; no statistical significance vs. C-MV (one way analysis of variance, Holm-Sidak method). (E) GL261
cell proliferation was measured as % mean ± SE of BrdU+ GL261 cells untreated (no-MV), treated with MV obtained from untreated microglia (C-MV), microglia
treated with LPS/IFNγ (LPS/IFNγ-MV) and IL 4 (IL 4-MV) for 24 h, N = 4, no statistical significance vs. C-MV (one way analysis of variance, Holm-Sidak method).
(F) GL261 cells, co-cultured with hippocampal neuroglial cultures (as depicted in the inset) were treated for 18 h with MV obtained from untreated microglia (C-MV),
microglia treated with LPS/IFNγ (LPS/IFNγ-MV) and IL 4 (IL 4-MV), were analyzed for viability by trypan Blue staining. Data are expressed as number of viable
cells/field ± SE, N = 3; ∗∗ P < 0.05, Student’s t-test. (G) Hippocampal neuroglial cultures alone or co-cultured with GL261 cells (as depicted in the inset of panel F)
were treated with MV obtained from untreated microglia (C-MV), microglia treated with LPS/IFNγ (LPS/IFNγ-MV) and IL 4 (IL 4-MV) for 18 h and were analyzed for
neuronal viability. Data are expressed as number of viable cells/field ± SE, N = 3, ∗P < 0.001, Student’s t-test.
FIGURE 3 | Tumor size in the brain of GL261-bearing mice treated with
vehicle or MV obtained from microglia treated with LPS/IFNγ (LPS/IFNγ-MV)
and IL 4 (IL 4-MV). Tumor size (in mm3) was reported as mean ± SE,
N = 7/experimental group, ∗P < 0.05, ∗∗p ≤ 0.001 vs. vehicle, Student’s
t-test. On the top, representative coronal brain sections of GL261-bearing
mice treated as above, stained with hematoxylin-eosin; tumor area in the
dashed line.
2 h before euthanasia. Quantification of BrdU-labeled cells,
normalized for tumor area, revealed a significant reduction
of cell proliferation in the tumoral region (Figure 4A) of
LPS/IFNγ-MV treated mice. Treatment with LPS/IFNγ-MV
also reduced glioma cell migration in vivo, as reported in
Figure 4B, where tumor cell invasion was calculated as the
number of cells protruding more than 150 µm from the
main tumor mass. In the peritumor region, we evaluated
neuronal death by Fluoro Jade staining, comparing mice
treated with LPS/IFNγ-MV with control mice. Data shown in
Figure 4C demonstrate that neuronal death was significant
reduced in LPS/IFNγ-MV treated mice, demonstrating
in vivo a neuroprotective effect of LPS/IFNγ-MV against
tumor-induced excitotoxicity.
All these data demonstrated that LPS/IFNγ-MV carry
anti-tumor information that are effective in reducing tumor
size in vivo.
Microglia-Derived LPS/IFNγ-MVs Modify
the Phenotype of Tumor-Associated
Microglia
To understand the mechanisms of action of the injected MVs,
we first decided to investigate their cellular localization upon
brain injection. At this aim, MVs derived from primary microglia,
were stained with the membrane-selective dye PKH26 and brain
injected in glioma bearing mice. Cerebral slices obtained from the
tumoral region show the presence of PKH26-MV on both Iba1−
and Iba1+ cells (Figure 5A). We never observed PKH26 staining
outside the tumor area. It is known that a high amount of tumor
associated microglia/macrophages (TAMs) are present in glioma,
and may represent up to 50% of tumor mass (Hambardzumyan
et al., 2016). TAMs exert tumor supporting function releasing
factors that facilitate tumor proliferation and migration (Fonseca
et al., 2012). We wonder whether the interaction of MVs with
TAMs could modulate their pro-tumor activity, and investigated
the effect of LPS/IFNγ-MV on gene expression of CD11+ cells
isolated from the brains of glioma-bearing mice. As shown
in Figure 5B, the expression of arg1, cd163, cd206, fizz1, and
ym1 genes all correlated with an anti-inflammatory, pro-tumor
phenotype, were up-regulated in CD11b+ cells in the ipsilateral
hemisphere of glioma bearing mice and were significant reduced
upon LPS/IFNγ-MV treatment (with the exception of fizz1).
Similar modulatory effects were observed in vitro: as shown
in Figure 5D, LPS/IFNγ-MV (derived from primary microglia)
significant reduced the microglial expression of all analyzed
genes (arg1, cd163, cd206, ym1, and fizz1) except ym1, indicating
a direct modulation likely induced by MV cargo that enter
microglia also in vitro (Figure 5C).
All these data suggest that LPS/IFNγ-MVs might directly
signal to microglia and instruct these cells toward an
antitumor phenotype.
mRNA Analyses of Microglia-Derived
LPS/IFNγ-MV
To investigate the nature of the cargo transported by
LPS/IFNγ-MV that could help the understanding of the
above described mechanisms, the mRNA content of MVs
Frontiers in Cellular Neuroscience | www.frontiersin.org 5 February 2019 | Volume 13 | Article 41
fncel-13-00041 February 21, 2019 Time: 14:9 # 6
Grimaldi et al. Microglial EVs in Brain Tumors
FIGURE 4 | (A) Cell proliferation, measured as BrdU+ cell area/tumor area in GL261-bearing mice treated with vehicle or MV obtained from microglia treated with
LPS/IFNγ (LPS/IFNγ-MV), data are expressed as mean percentage ± SE, N = 3, ∗∗P ≤ 0.001 vs. vehicle, Student’s t-test. On the right: representative
immunofluorescence on coronal brain slices of GL261-bearing mice treated as above (BrdU in green; Hoechst in blue), scale bars, 20 µm. (B) Glioma cells invading
the brain parenchyma for more than 150 µm beyond tumor border 17 days after glioma cell transplantation in GL261-bearing mice treated with vehicle or MV
obtained from microglia treated with LPS/IFNγ (LPS/IFNγ-MV), data are expressed as mean cell number ± SE, N = 3/experimental group, ∗∗P ≤ 0.001, Student’s
t-test vs. vehicle. On the right, representative brain peritumoral sections stained with haematoxylin/eosin; white arrows indicate glioma cells invading the brain
parenchyma beyond the main tumor border for more than 150 µm (dashed line); scale bars, 20 µm. (C) Neuronal death, measured as Fluoro Jade+ cells/tumor area
in GL261-bearing mice treated with vehicle or MV obtained from microglia treated with LPS/IFNγ (LPS/IFNγ-MV), data are expressed as mean percentage ± SE,
N = 3, ∗∗P ≤ 0.001 vs. vehicle, Student’s t-test. On the right: representative immunofluorescence on coronal brain slices of GL261-bearing mice treated as above
(Fluoro Jade in green; Hoechst in blue), scale bars, 20 µm.
released by primary microglia was analyzed by NanoString chip
for the expression of 243 key inflammation-related genes and
compared with MVs released by control, unstimulated microglia.
As shown on Figure 6A, 18 genes were significantly up-regulated
in LPS/IFNγ-MV. Data were confirmed by RT-PCR for tnf-α and
il1b genes (Figure 6B), validating the immune panel system.
Pathway analysis, performed on the 10 most significant
functional categories defined by the Gene Ontology Biological
process (Figure 6C) indicated that LPS/IFNγ-MV contain 12%
of genes involved in inflammatory responses (c3, ccl4, ccl5, cxcl2,
cxcl9, tnf, ptgs2, ccl7, il1b, ccl2, ccl3, il1rn, hif1a), 14% of genes
involved in defense responses (irf7, c3, ccl4, ccl5, cxcl2, cxcl9, tnf,
ptgs2, mx1, ccl7, il1b, ccl2, ccl3, il1rn, hif1a), 12% of genes involved
in responses to wounding (c3, ccl4, ccl5, cxcl2, cxcl9, tnf, ptgs2,
ccl7, il1b, ccl2, ccl3, il1rn, hif1a), 12% of genes involved in immune
responses (irf7, c3, ccl4, ccl5, cxcl2, cxcl9, tnf, mx1, ccl7, il1b, ccl2,
ccl3, csf3), 4% of genes involved in regulation of natural killer cell
chemotaxis (ccl7, ccl4, ccl3, ccl2, ccl5), 8% of genes involved in
positive regulation of response to external stimuli (c3, ccl4, ccl5,
tnf, ccl7, ptgs2, il1b, ccl2, ccl3), 10% of genes involved in regulation
of cytokine production (irf7, c3, ccl4, ccl5, tnf, ptgs2, il1b, ccl2, ccl3,
hif1a, cebpb), 13% of genes involved in immune system process
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FIGURE 5 | (A) Immunofluorescence analysis for Iba1 (in green) of coronal brain sections from GL261-bearing mice treated with PKH26-stained MV (in red; Hoechst
in blue) obtained from microglia. Tumor region at the right of the dashed line. In the merge, identification of two tumor regions shown at higher magnification. Scale
bar: 20 µm (B) RT-PCR of anti-inflammatory genes (arg1, cd163, cd206, ym1, and fizz1) in CD11b+ cells extracted from brains of GL261-bearing mice treated with
vehicle or MV obtained from microglia treated with LPS/IFNγ (LPS/IFNγ-MV). Data are the mean ± SE of fold increase (normalized vs. contralateral cerebral
hemisphere of each animal; gene expression was normalized vs. gapdh), N = 5, ∗∗P < 0.001, ∗P < 0.05 vs. vehicle treated mice, Student’s t-test. (C) Merged of
bright and fluorescence fields of microglia treated with IL 4 and incubated with PKH26-stained MV (in red) obtained from LPS/IFNγ-treated microglia. (D) RT-PCR on
mRNAs of untreated or IL 4-treated microglia incubated with or without MV obtained from LPS/IFNγ-treated microglia, and analyzed for the expression of
anti-inflammatory genes (arg1, cd163, cd206, fizz1, and ym1). Data are the mean ± SE of fold increase (normalized vs. gapdh), N = 3, ∗∗P < 0.001, ∗P < 0.05,
Student’s t-test.
(irf7, c3, ccl4, ccl5, cxcl2, cxcl9, tnf, mx1, ccl7, il1b, ccl2, ccl3, hif1a,
csf3), 8% of genes involved in positive regulation of cytokine
production (irf7, c3, ccl4, ccl5, tnf, ptgs2, il1b, ccl3, hif1a), and
7% of genes involved in leukocyte migration (ccl4, ccl5, cxcl2, tnf,
ccl7, il1b, ccl2, ccl3). These data demonstrated that the MV mRNA
content is highly complex, covering genes coding for proteins
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FIGURE 6 | (A) mRNAs isolated from MV released by untreated microglia (C-MV) or microglia treated with LPS/IFNγ (LPS/IFNγ-MV) were analyzed by NanoString.
Heat map analysis of NanoString data show hierarchical clustering of 18 differentially expressed genes between C-MV and LPS/IFNγ-MV, N = 4. The signals were
normalized and transformed to the log2 scale. The color scale indicates the gene expression standard deviations from the mean, with black/blue for low expression
and green/orange for the high expression levels. Eighteen genes (listed on the right) were considered significant because with at least 2.8-fold changes with
P < 0.05 (Wilcoxon test) at the 95% confidence level. Dendrograms illustrate the relationship-distance between samples and genes. (B) RT-PCR on mRNAs isolated
from MV derived from untreated microglia (C-MV) or microglia treated with LPS/IFNγ (LPS/IFNγ-MV) analyzed for the expression of il1b and tnf genes. Data are the
mean ± SE of fold increase (normalized vs. gapdh), N = 3, ∗P < 0.05, Student’s t-test vs. C-MV. (C) The pie chart illustrates the distribution of the 18 differentially
expressed genes across the 10 most significant functional categories defined by the Gene Ontology Biological process. The percentage numbers represent the
frequency of genes in each category. Data were analyzed using FIDEA tool.
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related to different pathways of the inflammatory process, and
that their delivery to TAM might contribute to re-activate the
immune response, which oppose glioma growth.
MATERIALS AND METHODS
Primary Brain Cells Cultures
Neuroglial cultures were prepared from 0- to 2-day-old (p0–
p2) C57BL/6N mice as already described (Lauro et al.,
2010); neurons-astrocytes-microglia ratio is 60-35-5%. Microglia
cultures were obtained as already reported (Grimaldi et al., 2016)
and were 98% Iba1+ positive (Lauro et al., 2010).
Cell Lines
BV2 murine microglial cells and GL261 murine glioma cells were
cultured in DMEM supplemented with 10–20% heat-inactivated
FBS, 100 IU/ml penicillin G, 100 µg/ml streptomycin, 2.5 µg/ml
amphotericin B and grown at 37◦C in a 5% CO2 and humidified
atmosphere.
Microglia Stimulation (Polarization)
Primary microglia and BV2 cells were treated for 24 hours with
IFN-γ (20 ng/ml) and LPS (100 ng/ml), or with IL-4 (20 ng/ml)
or with EVs.
Extraction of EVs
Cytokine-treated microglia were stimulated for 30 min with
ATP (1 mM) in KRH (125 mM NaCl; 5 mM KCl; 1.2 mM
MgSO4; 1.2 mM KH2PO4; 2 mM CaCl2; 6 mM D-glucose;
25 mM HEPES/NaOH, pH = 7.4). Cell supernatant was
collected and centrifuged at 800 g for 5 min to remove cell
debris. The obtained supernatant was centrifuged at 10000 g
for 30 min at 4◦C and the resulting pellet, containing
MVs, was re-suspended in KRH buffer for DLS, LTS and
transmission electron microscopy, in PBS for in vivo experiments
or in serum-free DMEM for microglia stimulation, MTT,
wound healing and BrDU proliferation assays. Remaining
supernatant underwent ultracentrifugation at 100,000 g for
1-h at 4◦C. The Exo, present in this second pellet, were
re-suspended in KRH buffer for DLS measures and in
serum free DMEM for wound healing assay. The same
protocol permits to eliminate EVs from the medium used
to re-suspend MVs and Exo and guarantees that the EVs
obtained only derived from polarized microglial cells. In
some experiments, EVs were labeled with PKH26, a lipophilic
membrane red fluorescent dye (PKH26 GL-1KT, Sigma-
Aldrich) according to manufacturer protocol. Briefly, PKH26
dye was re-suspended in diluent C to a final concentration
of 0.6 µM (dye solution). MV were re-suspended in 500 µL
of dye solution and incubated for 5 min, while mixed with
gentle pipetting. Excess dye was bound with 500 µL EVs-
depleted bovine serum albumin (1%, Sigma-Aldrich). MV
pellet, obtained by centrifugation (10000 × g, 30 min, 4◦C)
was washed twice in PBS. PKH26-stained MV were re-
suspended in PBS for in vivo administration and in serum-
free DMEM for in vitro treatment. In all the experiments,
the same procedure of staining minus MV was performed as
control condition.
Dynamic Light Scattering and Data
Analysis
Dynamic light scattering (DLS) measurements were performed
using a standard optical setup. The monochromatic and
polarized beam emitted from a He-Ne laser (10 mW at
λ = 632.8 nm) was focused on the sample placed in a capillary
of 2 mm of diameter positioned in a cylindrical VAT for
index matching and temperature control. The scattered
intensity was collected at a scattering angle θ = 90◦that,
according to the relation Q = (4pin/λ) sin(θ/2), corresponds
to a scattering vector Q = 0.0187 nm−1. A single mode
optical fiber collected the scattered light as a function of
time and the signal was detected by a photomultiplier.
In this way the normalized intensity autocorrelation
function g2(Q,t) = < I(Q,t)I(Q,0)>/<I(Q,0) >2 with a
high coherence factor close to the ideal unit value was
measured. Measurements were performed at fixed temperature
around 15◦C. Reproducibility has been tested by repeating
measurements several times on different samples. The intensity
correlation curves obtained from DLS experiments have been
analyzed with the Laplace inversion through the CONTIN
algorithm weighted as overall contribution to the scattered
intensity. However, the scattered intensity depends on the
squared volume of the scattering particle, thus leading to an
overestimation of the large particles. Therefore, this approach
has good reliability for samples of EVs, whose hydrodynamic
diameter is expected in the range Dh = 100÷1000 nm. On
the other hand, small particles are under-represented in the
intensity-weighted distribution and Laplace transformation
can be very inaccurate. To represent the hydrodynamic
diameter distribution of Exo with size expected in the range
Dh = 10÷100 nm the volume-weighted distribution has
been chosen. The mean size of each population has been
calculated by fitting the scattering intensity distribution with a
Log-normal function.
Laser Transmission Spectroscopy
Laser Transmission Spectroscopy (LTS) allows to obtain the
density of MV in suspension by measuring the transmission of
laser light (at zero angle with respect to the incoming beam)
through the suspension as a function of wavelength (Li et al.,
2010). The transmission of light through the MV sample (re-
suspended in KRH) is recorded along with that of KRH. The
fundamental data-acquisition process involves measuring the
wavelength-dependent transmission of light through an aqueous
suspension of vesicles. Given the extinction information, and
the known wavelength-dependent properties of the vesicles,
Mie theory can be used to accurately determine their density
distribution as a function of diameter. The extinction data are
analyzed and inverted by a mean square root-based algorithm
that outputs the particle size distribution. The integral of the
density distribution provides the number of MV per ml of
solution and the absolute number (N) of MV per cell is calculated
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as the ratio between the number of MV in a given volume and the
total number of MV donor cells.
Transmission Electron Microscopy
Microvesicles derived from BV2 cells (extracted as above) were
fixed by glutaraldehyde 2.5% in PBS buffer pH 7.4 at least 2 h and
gently resuspended in PBS buffer. A drop of the solution was put
on a Formvar copper grid 200 mesh for 10 min. After drying with
filter paper, uranyl acetate aqueous solution (1%, 1 min) was used
for negative staining. Samples were observed with a ZEISS EM 10
transmission electron microscope equipped with a Gatan CCD
camera at 60 kw.
Neuronal Viability Assay
Neuroglial cultures at 9–11 days in vitro were co-cultured with
GL261 cells (5× 104/well) in the presence or absence of EVs with
a ratio of donor:target cells 1:1. After 18 h, cells were treated with
detergent-containing buffer and counted in a haemocytometer as
already described (Lauro et al., 2010).
MTT Cell Viability Assay
GL261 cells were seeded into 24-well plates and treated with
vehicle (untreated), IFN-γ /LPS- or IL 4-MV for 3 days. MTT
(500 µg/ml) was added into each well for 1.5 h. DMSO was
then added to stop the reaction and the formazan produced
was measured at 570 nm. Viability of cells was expressed
relative to absorbance.
Wound-Healing Assay
GL261 cells (5 × 105/ml) were seeded into the inner wells
of cell culture inserts (ibidi, Germany) placed in a Petri dish.
Once attached to the substratum, the inserts were removed,
leaving a central 500 µm cell-free septum in which cells could
migrate. Cell medium with MV released by IFN-γ /LPS- or
IL 4-treated microglia (ratio 1:1 = donor: target cells) was
added. Cells were incubated with a cell cycle blocker (cytarabine,
10 µM) to prevent GL261 proliferation for all the time of the
experiment. Dishes were maintained at 37◦C, 5% CO2. Pictures
of the starting point (0 h) and 24 and 48 h after treatment were
taken at a phase contrast microscope (Nikon) and processed
through MetaMorph 7.6.5.0 software (Molecular Device). GL261
migration was evaluated by the area between the two cell fronts
(by ImageJ software) and data are expressed as % of area
occupied by cells.
Invasion Assay
GL261 cells (7 × 103 cells/cm2) were plated on matrigel-coated
polycarbonate membranes (8 µm diameter pores, Corning) of
a Boyden Chamber system in presence of IFN-γ /LPS-MV or
IL 4-MV (ratio 1:1 donor:target cells) and incubated for 48 h at
37◦C with CXCL12 (100 nM, Peprotech) in the lower chamber as
chemoattractant. The experiments were performed in presence
of cytarabine (10 µM). Cells adhering to the upper side of the
membranes were scraped off, whereas cells that have invaded
through the pores were stained with a solution containing 50%
isopropanol, 1% formic acid, and 0.5% (wt/vol) brilliant blue R
250 and counted in more than 20 fields with a 20× objective.
In vivo Experiments
Experiments were approved by the Italian Ministry of Health,
in accordance with the ethical guidelines on use of animals
from the EC Council Directive 2010/63/EU. Eight-week-old
male C57BL/6N mice were injected with GL261, as previously
described (Grimaldi et al., 2016), in the right striatal brain region.
During surgery, a guide cannula was placed 2 mm deep in the
striatum and it was fixed with quick-setting cement. After 7 and
14 days, mice were infused via cannula with MVs obtained from
1 × 106 microglia cells re-suspended in 4 µl PBS). The day
after the second infusion, animals were sacrificed and analyzed
for tumor size (Grimaldi et al., 2016). Alternatively, mice were
deeply anesthetized and CD11b+ cells were isolated as already
described (Grimaldi et al., 2016). Obtained cells were lysed in
Trizol reagent (Invitrogen, Milan, Italy) for RNA extraction and
Real Time PCR analysis.
BrdU Proliferation Assay
GL261 cells were grown on glass coverslips (1.5 × 104 cells/cm2)
in 24-well plates for 18 h. Cells were exposed to vehicle or
EV for 24 h, cellular proliferation was analyzed adding BrdU
(10 µM, Sigma-Aldrich, B5002) for 30 min. Cells were washed
in PBS, fixed (4% PFA, 30 min), permeabilized (1% Triton X-100,
15 min), blocked (1% BSA, 1 h) at RT and incubated overnight
with anti-BrdU (1:200, Novusbio, NB500-169). Hoechst was
used to stain all nuclei. BrdU positive cells were counted out
of 800 cells for condition. Proliferation rate is calculated as
BrdU+ cells respect to Hoechst stained cells. In vivo, 15 days
after glioma cell injection, BrdU was i.p. injected (50 mg/kg).
Two hours later, mice were killed and their brains processed
for immunofluorescence.
Immunofluorescence
Coronal brain sections (20µm) were washed in PBS, blocked (3%
goat serum in 0.3% Triton X-100) for 1h at RT and incubated
with anti-Iba1 (1:500, Wako, 019-19741, 4◦C) or anti-BrdU
(1:200, Novusbio, NB500-169, RT). Brain slices were stained
with the fluorophore-conjugated secondary antibodies (1 h,
RT) and Hoechst for nuclei visualization and analyzed using a
fluorescence microscope. For Fluoro Jade-C staining, we followed
the manufacturer instructions (Millipore, AG325).
Real Time PCR
RNAs extracted from all samples were quantified and retro-
transcribed using IScriptTM Reverse Transcription Supermix
(Bio-Rad). Real time PCR (RT-PCR) was carried out in an
I-Cycler IQ Multicolor RT-PCR Detection System (Bio-Rad)
using SsoFast Eva Green Supermix (Bio-Rad). The PCR
protocol consisted of 40 cycles of denaturation at 95◦C
for 30 s and annealing/extension at 58◦C for 30 s. The Ct
values from each gene were normalized to the Ct value
of GAPDH. Relative quantification was performed using
the 2−11Ct method and expressed as fold increase. Primer
sequences: arg1, forward: CTCCAAGCCAAAGTCCTTAGAG,
reverse: AGGAGCTGTCATTAGGGACATC; cd163 forward:
GCTAGACGAAGTCATCTGCACTGGG, reverse: TCAGCCT
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CAGAGACATGAACTCGG; cd206 fw: CAAGGAAGGTTGG
CATTTGT, reverse: CCTTTCAGTCCTTTGCAAGT; ym1
forward: CAGGTCTGGCAATTCTTCTGAA, reverse: GTCT
TGCTCATGTGTGTAAGTGA; fizz1 forward: CCAATCCA
GCTAACTATCCCTCC, reverse: ACCCAGTAGCAGTCA
TCCCA; gapdh forward: TCGTCCCGTAGACAAAATGG,
reverse: TTGAGGTCAATGAAGGGGTC.
RNA Isolation and NanoString nCounter
Analysis
Total RNA was isolated from microglia-derived MV by Total
Exosome RNA Protein Isolation Kit (# 4478545, Invitrogen)
and concentrated using the Microcon10 centrifugal filters
(#MRCPRT010, Merck Millipore). Gene expression raw data
were normalized considering housekeeping genes via nSolver
Software (NanoString). Statistical analysis was conducted in R
(version 3.5.0) with RStudio (version 1.1.3831). On normalized
and log2-transformed data, differential expression was tested
applying the Wilcoxon test (P < 0.05) and filtering by
log2FC > 1.5. All differentially expressed genes were classified
into several catalogs according to the Gene Ontology (GO)
annotation. The over-representation analyses of GO terms,
including biological process and molecular function, were
performed using the FIDEA tool2.
Statistical Analysis
Statistical analyses were performed using SigmaPlot 11.0
Software unless otherwise stated.
DISCUSSION
The present study demonstrated that microglia-derived
LPS/IFNγ-MV transfer a protective-antitumor phenotype
to the brain of glioma bearing mice. We demonstrated that
LPS/IFNγ-MV, which contain the transcripts for a number
of inflammation-related genes, can modify TAMs phenotype
reducing the expression of anti-inflammatory genes, exert
protective effects on neurons and reduce glioma cell proliferation
and invasion in surrounding parenchyma.
We have shown that LPS/IFNγ-MV contain 18 genes
upregulated in comparison with MV isolated by unstimulated
microglia. The majority of these genes referred to the immune
response that could underlie the robust effect of MV on the
modification of microglia phenotype. It is known that many
solid tumors, such as colon-rectal, epithelial ovarian, brain and
lung cancers, release EVs which are involved in supporting TAM
reprogramming toward an anti-inflammatory, tumor-supporting
phenotype (Fabbri et al., 2012; Challagundla et al., 2015; Neviani
and Fabbri, 2015; Chen et al., 2017; Shinohara et al., 2017;
Cooks et al., 2018). Our findings demonstrated that in the
context of a brain tumor, microglia-derived MV can be used
in reverse, as a tool to contrast glioma progression, modulating
local microenvironment.
1http://www.rstudio.com/
2http://circe.med.uniroma1.it/fidea/
Previous reports described that EVs released from LPS
stimulated BV2 cell line contain cytokines such as TNF-α
and IL-6, as well as ribosome, focal adhesion, extracellular
matrix, and membrane proteins (Yang et al., 2018). BV2-
derived EVs expressing the cytokine IL-4, delivered in a mouse
model of multiple sclerosis, propagated an anti-inflammatory
response, upregulating microglia and macrophage expression of
chitinase 3-like 3 (ym1) and arginase (arg-1), which reduced
neuroinflammation with protective effects on tissues (Casella
et al., 2018). Consistently, we observed that the EVs released
by cytokine-stimulated microglia maintain the phenotype of
the donor cells. This result is in line with the evidence that
vesicles released by macrophages and dendritic cells reflect the
inflammatory state of original cells (Kim et al., 2005; Viaud et al.,
2009; Garzetti et al., 2014).
Microvesicle are supposed to transfer their cargo by docking
at the plasma membrane of target cells, nevertheless the exact
mechanism is not fully revealed. This interaction is neither
stochastic nor unspecific because MV do recognize the target
cells (Losche et al., 2004). The recognition takes place by
activation of specific surface receptors (Gasser and Schifferli,
2004; Bianco et al., 2005), or by transfer of membrane receptors,
as demonstrated for the chemokine receptor CCR5 (Mack
et al., 2000) and the growth factor receptor EGFRvIII (Al-
Nedawi et al., 2008). MV could function as messengers, being
enriched in specific miRNA, mRNA, and proteins, to start
an angiogenic program (Deregibus et al., 2007), to spread a
danger signal through HMGB1 (Tucher et al., 2018) or to
induce a developmental program (Ratajczak et al., 2006). In
our experiments, we measured mRNA content of microglia
released LPS/IFNγ-MV, but we cannot exclude additional
transfer elements (such as membrane or signal proteins) from
MV to glioma and TAM, responsible for the antitumor effects.
In addition to a modulation of TAM phenotype, we observed
that LPS/IFNγ-MV affect glioma cell properties. We observed
direct effects on glioma cell migration and invasion capability,
and indirect effects on tumor cell viability, which requires the
presence of parenchymal cells, likely microglia, as preferential
target of microglia-derived EVs (Verderio et al., 2012). The
effects of microglia-derived MV on GL261 cells could reflect
the transfer of cell-donor information as reported for the first
time for antigen-presenting cells that secrete exosomes able to
stimulate T cell proliferation (Raposo et al., 1996) or, more
recently in Alzheimer disease, for microglia released MV that
exert toxicity on neurons (Joshi et al., 2014). In our experiments,
EV-mediated reduction of tumor mass could be the cause of the
EV-induced decreased neurotoxicity in the presence of glioma.
However, we cannot exclude that EVs also directly target neurons,
as shown by other authors (Antonucci et al., 2012; Chivet
et al., 2014), but the lack of detectable PKH26-MV staining in
extra tumoral regions of glioma bearing mice would suggest a
direct or local paracrine effect. In addition, in vitro experiments
demonstrated that microglia-derived MVs did not directly affect
neuron viability.
The dimensional analyses of EVs extracted by primary
mouse microglia and BV2 cell line reflect data reported on
nervous system-released vesicles (Basso and Bonetto, 2016;
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Zappulli et al., 2016) and underline the similarity between
primary microglia and cell lines, at least for EV dimension.
Our TEM analysis shows that single particles have a spherical
morphology; in addition to single EV, multiple aggregates are
observed confirming size and shape already reported for EVs
derived from microglial cells (Turola et al., 2012; Gouwens et al.,
2018). In comparison with more physiological conditions (in vivo
or ex vivo), cell lines and primary cultures of microglia display
many differences in term of gene expression and response to
stimuli (Horvath et al., 2008; Henn et al., 2009). However, there
are evident advantages in using EVs derived from microglia cells
lines, such as the possibility to obtain sufficient EVs for potential
therapeutic application and the similar results obtained with MV
from BV2 or from freshly isolated microglia encourage in this
direction. However, a detailed analysis of the cargo differences
in MV obtained from cell lines, cultured or freshly obtained
microglial cells is lacking.
The choice to deliver MV in situ into the tumor region allowed
us to use a relatively small amount of vesicles per infusion and to
observe a direct effect on tumor mass. Different brain delivery of
EVs, as into the cisterna magna (Casella et al., 2018), would give
additional information on the effects of EVs in the contralateral
hemisphere, for the multicellular targets of EVs. Additional
delivery methods were tested for EVs, such as the intravenous
(Alvarez-Erviti et al., 2011) and intra-nasal (Zhuang et al., 2011)
approach. Intravenous administration permits indirect access of
MV to the brain through the initial absorption in different cells
(Laso-García et al., 2018). Intranasal delivery might reduce the
final brain concentration due to lungs and gastrointestinal tract
dilution. Nevertheless, both delivering routes would be easily
reproduced in humans, while intratumor transfer would be only
possible upon surgery procedures during glioma removal. For
that reason, alternative EV injection routes, in glioma models,
need further investigations. For brain tumor treatment, EVs
have been tested to convey specific molecules such as small
interference RNAs for TGF beta 1 and VEGF (Zhang et al., 2014;
Yang et al., 2017), pro-apoptotic peptides (Ye et al., 2018), and
chemotherapeutic drugs (Tang et al., 2012; Yang et al., 2015).
EVs are preferred to artificial nanoparticles for their low toxicity
(Lewinski et al., 2008; Shvedova et al., 2010).
To our knowledge, this is the first evidence that, in the context
of a brain glioma, microglia-derived MVs can be used to transfer
a cargo of molecular information that reach TAM restoring a
neuroprotective phenotype, modulating their inflammatory state
and re-establishing a homeostatic brain microenvironment.
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